GRFS
GrifolsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Composite grade D from latest DB weights. Momentum 14.2 / Value 66.8
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
14
Value
67
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $14.43
Why
Momentum14 · Δ7d +1.9
Value67 · Δ7d -0.3
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
14
40% active weight
Current posture
7d trendImproving
Δ7d
+1.9
Δ21d
-5.6
Value
67
60% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.5
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 14.2 / Value 66.8
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$6.69B
Beta
1.57
Shares Out
258.22M
P/E (TTM)
20.7
P/S (TTM)
0.92
P/FCF (TTM)
9.90
Rev YoY
+5.8%
EPS YoY
+35.8%
Gross Margin
+37.0%
Op Margin
+17.9%
Net Debt
$9.3B
Current Ratio
2.47
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology